Daniel A Solomon1, Paul E Sax. 1. Division of Infectious Diseases, Brigham and Women's Hospital, 75 Francis Street Boston, MA, USA.
Abstract
PURPOSE OF REVIEW: We aim to review the strengths and weaknesses of current antiretroviral therapy (ART), and describe ongoing research to address limitations to current therapy. RECENT FINDINGS: Current ART is highly effective and well tolerated. As a result of a decrease in medication side-effects and pill burden, and the known health effects of uncontrolled viremia, ART is now recommended at all CD4 cell counts in the USA. Novel medications are being developed to further decrease side-effects and offer alternative options for patients with multiclass resistance. New combination pills will further decrease pill burden. SUMMARY: Current treatment for HIV is characterized by highly potent oral antiretroviral medications, which are well tolerated, resulting in outstanding rates of virologic suppression in patients who are adherent to therapy. Despite the marked improvement in therapeutic options, limitations to therapy still exist including reliance on daily adherence, long-term toxicity of medications, drug-drug interactions, long-term effects of HIV even in the setting of viral suppression, high lifetime cost of treatment, and limited options for some patients with multiclass resistance. Emerging alternative treatment strategies include nucleoside reverse transcriptase inhibitor-sparing or limiting regimens and long-acting injectable combination therapy.
PURPOSE OF REVIEW: We aim to review the strengths and weaknesses of current antiretroviral therapy (ART), and describe ongoing research to address limitations to current therapy. RECENT FINDINGS: Current ART is highly effective and well tolerated. As a result of a decrease in medication side-effects and pill burden, and the known health effects of uncontrolled viremia, ART is now recommended at all CD4 cell counts in the USA. Novel medications are being developed to further decrease side-effects and offer alternative options for patients with multiclass resistance. New combination pills will further decrease pill burden. SUMMARY: Current treatment for HIV is characterized by highly potent oral antiretroviral medications, which are well tolerated, resulting in outstanding rates of virologic suppression in patients who are adherent to therapy. Despite the marked improvement in therapeutic options, limitations to therapy still exist including reliance on daily adherence, long-term toxicity of medications, drug-drug interactions, long-term effects of HIV even in the setting of viral suppression, high lifetime cost of treatment, and limited options for some patients with multiclass resistance. Emerging alternative treatment strategies include nucleoside reverse transcriptase inhibitor-sparing or limiting regimens and long-acting injectable combination therapy.
Authors: Sarah Lilian Pett; Janaki Amin; Andrejz Horban; Jaime Andrade-Villanueva; Marcelo Losso; Norma Porteiro; Juan Sierra Madero; Waldo Belloso; Elise Tu; David Silk; Anthony Kelleher; Richard Harrigan; Andrew Clark; Wataru Sugiura; Marcelo Wolff; John Gill; Jose Gatell; Martin Fisher; Amanda Clarke; Kiat Ruxrungtham; Thierry Prazuck; Rolf Kaiser; Ian Woolley; Juan Alberto Arnaiz; David Cooper; Jürgen K Rockstroh; Patrick Mallon; Sean Emery Journal: Clin Infect Dis Date: 2016-04-05 Impact factor: 9.079
Authors: Dirk Schürmann; Deanne Jackson Rudd; Andrea Schaeffer; Inge De Lepeleire; Evan J Friedman; Martine Robberechts; Saijuan Zhang; Yang Liu; Bhargava Kandala; Christian Keicher; Martin Däumer; Jörg Hofmann; Jay A Grobler; S Aubrey Stoch; Marian Iwamoto; Wendy Ankrom Journal: J Acquir Immune Defic Syndr Date: 2022-02-01 Impact factor: 3.771
Authors: Ifeanyi Jude Ezeonwumelu; Edurne García-Vidal; Eudald Felip; Maria C Puertas; Bruna Oriol-Tordera; Lucía Gutiérrez-Chamorro; André Gohr; Marta Ruiz-Riol; Marta Massanella; Bonaventura Clotet; Javier Martinez-Picado; Roger Badia; Eva Riveira-Muñoz; Ester Ballana Journal: Front Immunol Date: 2022-09-05 Impact factor: 8.786
Authors: Coral M Capó-Vélez; Manuel Delgado-Vélez; Carlos A Báez-Pagán; José A Lasalde-Dominicci Journal: Cell Mol Neurobiol Date: 2018-07-14 Impact factor: 4.231
Authors: Oluwadamilola Jolayemi; Laura M Bogart; Erik D Storholm; David Goodman-Meza; Elena Rosenberg-Carlson; Rebecca Cohen; Uyen Kao; Steve Shoptaw; Raphael J Landovitz Journal: PLoS One Date: 2022-02-03 Impact factor: 3.240